MapLight Therapeutics (MPLT) Common Equity (2024 - 2026)
MapLight Therapeutics (MPLT) posted Common Equity of $458.4 million for Q4 2025, up 267.18% sequentially from -$274.2 million in Q3 2025, and up 336.73% YoY from $105.0 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Common Equity (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Common Equity for 2 years, with the latest figure at $458.4 million in Q4 2025.
- Quarterly Common Equity rose 336.73% year-over-year to $458.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $458.4 million (up 336.73% YoY) and the FY2025 annual result came in at $458.4 million, up 336.73% from the prior year.
- Common Equity grew to $458.4 million in Q4 2025 per MPLT's latest filing, from -$274.2 million in the prior quarter.
- Over five years, Common Equity peaked at $458.4 million in Q4 2025 and troughed at -$274.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | 348.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 348.30 Mn |
| Dec 31, 2025 | 458.37 Mn |
| Sep 30, 2025 | -274.18 Mn |
| Jun 30, 2025 | -245.06 Mn |
| Dec 31, 2024 | -193.63 Mn |
| Sep 30, 2024 | -172.37 Mn |